| Interstitial pH and pO 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation G Helmlinger, F Yuan, M Dellian, RK Jain Nature medicine 3 (2), 177-182, 1997 | 1705 | 1997 |
| Solid stress inhibits the growth of multicellular tumor spheroids G Helmlinger, PA Netti, HC Lichtenbeld, RJ Melder, RK Jain Nature biotechnology 15 (8), 778-783, 1997 | 739 | 1997 |
| Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism G Helmlinger, A Sckell, M Dellian, NS Forbes, RK Jain Clinical Cancer Research 8 (4), 1284-1291, 2002 | 430 | 2002 |
| Effects of pulsatile flow on cultured vascular endothelial cell morphology G Helmlinger, RV Geiger, S Schreck, RM Nerem | 354 | 1991 |
| Formation of endothelial cell networks G Helmlinger, M Endo, N Ferrara, L Hlatky, RK Jain Nature 405 (6783), 139-141, 2000 | 190 | 2000 |
| Calcium responses of endothelial cell monolayers subjected to pulsatile and steady laminar flow differ G Helmlinger, BC Berk, RM Nerem American Journal of Physiology-Cell Physiology 269 (2), C367-C375, 1995 | 175 | 1995 |
| Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018 | 167 | 2018 |
| Pulsatile and steady flow-induced calcium oscillations in single cultured endothelial cells G Helmlinger, BC Berk, RM Nerem Journal of vascular research 33 (5), 360-369, 1996 | 100 | 1996 |
| Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients M Dellian, G Helmlinger, F Yuan, RK Jain British journal of cancer 74 (8), 1206-1215, 1996 | 91 | 1996 |
| A mechanistic tumor penetration model to guide antibody drug conjugate design C Vasalou, G Helmlinger, B Gomes PloS one 10 (3), e0118977, 2015 | 69 | 2015 |
| Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart D Bottino, RC Penland, A Stamps, M Traebert, B Dumotier, A Georgieva, ... Progress in biophysics and molecular biology 90 (1-3), 414-443, 2006 | 68 | 2006 |
| Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis KM Hallow, Y Gebremichael, G Helmlinger, V Vallon American Journal of Physiology-Renal Physiology 312 (5), F819-F835, 2017 | 47 | 2017 |
| Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ... Journal for immunotherapy of cancer 6 (1), 1-15, 2018 | 37 | 2018 |
| Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs A Kuttler, T Dimke, S Kern, G Helmlinger, D Stanski, LA Finelli Journal of pharmacokinetics and pharmacodynamics 37 (6), 629-644, 2010 | 37 | 2010 |
| An integrated approach for inference and mechanistic modeling for advancing drug development SV Aksenov, B Church, A Dhiman, A Georgieva, R Sarangapani, ... FEBS letters 579 (8), 1878-1883, 2005 | 34 | 2005 |
| Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018 | 23 | 2018 |
| Chap. 6 Shear stress effects on the morphology and cytomatrix of cultured vascular endothelial cells PR Girard Physical forces and the mammalian cell, 193-222, 1993 | 19 | 1993 |
| Implications of dynamic occupancy, binding kinetics, and channel gating kinetics for hERG blocker safety assessment and mitigation R A Pearlstein, K Andrew MacCannell, G Erdemli, S Yeola, G Helmlinger, ... Current topics in medicinal chemistry 16 (16), 1792-1818, 2016 | 15 | 2016 |
| Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes E Nyman, YJW Rozendaal, G Helmlinger, B Hamrén, MC Kjellsson, ... Interface focus 6 (2), 20150075, 2016 | 15 | 2016 |
| Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger Frontiers in immunology 10, 924, 2019 | 13 | 2019 |
